A randomized, double‐blind, placebo‐controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS‐CoV‐2 vaccine SCoK in adults

A randomized, double‐blind, placebo‐controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS‐CoV‐2 vaccine SCoK in adults

Abstract Background To determine an appropriate dose of, and immunization schedule for, a vaccine SCoK against COVID‐19 for an efficacy study; herein, we conducted randomized controlled trials to assess the immunogenicity and safety of this vaccine in adults. Methods These randomized, double‐blind,...

Full description

Bibliographic Details
Main Authors: Deyan Luo, Hongxing Pan, Peng He, Xiaolan Yang, Tao Li, Nianzhi Ning, Xin Fang, Wenjing Yu, Mingwei Wei, Hui Gao, Xin Wang, Hongjing Gu, Maodong Mei, Xinwang Li, Liangyan Zhang, Deyu Li, Chunrun Gao, Jinbang Gao, Guoqiang Fei, Ying Li, Yuguo Yang, Yi Xu, Wenjin Wei, Yansong Sun, Fengcai Zhu, Zhongyu Hu, Hui Wang
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Clinical and Translational Medicine
Subjects:
clinical trial
safety
SARS‐CoV‐2
vaccine SCoK
Online Access:https://doi.org/10.1002/ctm2.1016

Internet

https://doi.org/10.1002/ctm2.1016

Similar Items